the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
October 31, 2024 – Severe obesity is already a major problem for many children – all the more so because obese children very often become obese adults. There are currently no obesity medications for six to twelve year olds. Could …
Does the weight loss injection liraglutide also work in children? Read more »
January 13, 2019 – Are genetic variations in the sweet taste receptor gene related to chocolate powder and dietary fiber intake in obese children and adolescents? This was the question in a recent study just published in the Journal of …
Sweet taste receptor gene TAS1R2 and chocolate powder Read more »
March 26, 2017 – There is ample evidence that the burden of obesity is not the same across ethnic groups. While diet and lifestyle play a large role in determining body weight, there is also a heritable component. Unfortunately, most prior studies …
SEMA4D gene variant quadruples obesity risk in individuals of African descent Read more »
February 13, 2017 – If you are obese (or plain out fat), can you blame it on your genes? Actually, in very many cases, the answer is a qualified yes. Or a maybe. Under certain circumstances. Researchers are moving towards …
If you are obese, can you blame it on your genes? Read more »
Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF JAMA Dermatol 2016 Apr; PMID: 27120802 Abstract Importance: Psoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear. Objective: …
Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity Read more »
December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use …
The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA Read more »
September 13, 2014 – The U.S. Food and Drug Administration approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for …